Taysha Gene Therapies Inc (NAS:TSHA)
$ 5.02 -0.14 (-2.71%) Market Cap: 1.64 Bil Enterprise Value: 1.24 Bil PE Ratio: 0 PB Ratio: 4.22 GF Score: 33/100

Q1 2026 Taysha Gene Therapies Inc Earnings Call Transcript

May 06, 2026 / 12:30PM GMT
Release Date Price: $6.98 (+0.58%)
Operator

Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies first-quarter 2026 financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Hayleigh Collins, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Hayleigh Collins
Taysha Gene Therapies Inc - Senior Director, Corporate Communications and Investor Relations

Thank you. Good morning, and welcome to Taysha's first-quarter 2026 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended March 31, 2026. A copy of this press release is available on the company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot